KAT5

Histone acetyltransferase KAT5 · Q92993 · KAT5 on Sugi Atlas →

22,982 patent compounds predicted against KAT5, 14,891 high-confidence (nearest known ligand ≥ 0.5)

Top predicted compounds (top 20 by supporting neighbours, then confidence)

Compound	Confidence	Supporting neighbours
Anacardic Acid (SCHEMBL154720)	1.00	3/20
Gingkolic Acid (SCHEMBL163525)	0.84	3/20
SCHEMBL154719	0.77	3/20
SCHEMBL352817	0.31	3/20
Coenzyme_A (SCHEMBL26752)	1.00	2/20
Coenzyme_A (SCHEMBL26753)	1.00	2/20
Anacardic Acid (SCHEMBL627981)	1.00	2/20
SCHEMBL300853	0.97	2/20
Coenzyme_A (SCHEMBL614254)	0.95	2/20
Coenzyme_A (SCHEMBL61157)	0.90	2/20
Coenzyme_A (SCHEMBL88057)	0.88	2/20
SCHEMBL6086	0.86	2/20
SCHEMBL25252	0.84	2/20
SCHEMBL59684	0.84	2/20
SCHEMBL119813	0.84	2/20
SCHEMBL120458	0.84	2/20
SCHEMBL502465	0.84	2/20
Malonyl-Coenzyme A (SCHEMBL6450)	0.83	2/20
SCHEMBL59721	0.83	2/20
SCHEMBL60436	0.83	2/20

Clinical trials — most relevant to KAT5 by text similarity (a relevance ranking, not an exhaustive list)

Trial	Phase	Status
Compared the Efficacy and Safety of CDOP Combined With Chidamide and CDOP in de Novo Peripheral T Cell Lymphoma Patients	PHASE3	UNKNOWN
PhII 5-Azacytidine Plus Valproic Acid and Eventually Atra in Intermediate II and High Risk MDS	PHASE2	COMPLETED
Trial of the Histone-Deacetylase Inhibitor ITF2357 Followed by Mechlorethamine in Relapsed/Refractory Hodgkin's Lymphoma	PHASE1/PHASE2	COMPLETED
An Open-Label, Proof of Consent Study of Vorinostat for the Treatment of Mdoerate-to-Severe Crohn s Disease and Maintenance Therapy With Ustekinumab	PHASE1/PHASE2	RECRUITING
Phase 1/ Phase 2 Study to Assess Safety and Efficacy of Orally Administered JBI-802 in Subjects With Myeloproliferative Neoplasms (MPN) and Myelodysplastic/Myeloproliferative Neoplasms (MDS/MPN) With Thrombocytosis	PHASE1/PHASE2	RECRUITING
5-azacytidine Valproic Acid and ATRA in AML and High Risk MDS	PHASE2	COMPLETED
LBH589 Treatment for Refractory Clear Cell Renal Carcinoma	PHASE2	COMPLETED
IST Neoadjuvant Abraxane in Newly Diagnosed Breast Cancer	PHASE2	UNKNOWN
Relapsed and/or Refractory Non-Hodgkin Lymphoma Study	PHASE2	WITHDRAWN
Phase I/II Study of Decitabine and Valproic Acid in Relapsed/Refractory Leukemia or Myelodysplastic Syndromes	PHASE1/PHASE2	COMPLETED
Vorinostat in Treating Patients With Low-Grade Non-Hodgkin's Lymphoma	PHASE2	COMPLETED
Vorinostat in Children	PHASE1/PHASE2	COMPLETED
Enhancement of in-Vitro GC Function in Patients With COPD	PHASE2	COMPLETED
Pembrolizumab (MK-3475) in MM Patients With Residual Disease	PHASE2	COMPLETED
Research In Viral Eradication of HIV Reservoirs	PHASE2	COMPLETED
Phase I Dose Finding and Proof-of-concept Study of Panobinostat With Standard Dose Cytarabine and Daunorubicin for Untreated Acute Myeloid Leukemia or Advanced Myelodysplastic Syndrome	PHASE1	COMPLETED
A Phase I Study of Belinostat in Combination With Cisplatin and Etoposide in Adults With Small Cell Lung Carcinoma and Other Advanced Cancers	PHASE1	COMPLETED
Safety, Tolerability and Pharmacokinetics of Benfo-Oxythiamine (B-OT) in Healthy Volunteers	PHASE1	COMPLETED
Study of Cytolytic Viral Activation Therapy (CVAT) for Recurrent/Metastatic Nasopharyngeal Carcinoma	PHASE1	UNKNOWN
Panobinostat and Epirubicin in Treating Patients With Metastatic Malignant Solid Tumors	PHASE1	COMPLETED
Evaluation of the Safety and the Tolerability of a Combination of Two HIV Inducers in Patients With Undetectable Viral Load	PHASE1	COMPLETED
Chemoprevention of Head and Neck Squamous Cell Carcinoma (HNSCC) With Valproic Acid	EARLY_PHASE1	COMPLETED
Diagnosis of RSTS: Identification of the Acetylation Profiles as Epigenetic Markers for Assessing Causality of CREBBP and EP300 Variants.	nan	UNKNOWN
Epigenetic Evaluation of HAT/HDAC Activity in PBMC From Patients With Clinically Isolated Syndrome	nan	UNKNOWN
Effect of Exercise Gene Expression and Histone Modifications in Patients With Hemiplegia	nan	RECRUITING
Effect of Adenovirus E1A Oncogene on DNA Replication Dynamics	nan	UNKNOWN
CMOP Regimen and Chidamide in the Treatment of Newly Diagnosed Peripheral T-cell Lymphoma	nan	UNKNOWN
PHF19 Gene Expression and EZH2 Gene Deletion in Acute Myeloid Leukemia	nan	UNKNOWN
X-chromosome Inactivation, Epigenetics and the Transcriptome	nan	COMPLETED
Chi-GVM Regimen for the Treatment of R/R PTCL	nan	UNKNOWN

Related proteins — ESM-2 sequence neighbours (a KAT5 binder may also engage these)

Protein	Name	Similarity
Q8CHK4	—	1.000	Q8CHK4 →
Q99MK2	—	1.000	Q99MK2 →
KAT8	Histone acetyltransferase KAT8	1.000	landscape →
Q5XI06	—	1.000	Q5XI06 →
Q5RBG4	—	0.998	Q5RBG4 →
Q6C710	—	0.998	Q6C710 →
Q9D1P2	—	0.998	Q9D1P2 →
Q9TYU5	—	0.996	Q9TYU5 →
Q4IEV4	—	0.996	Q4IEV4 →
Q8LI34	—	0.995	Q8LI34 →
Q5SVQ0	—	0.995	Q5SVQ0 →
KAT7	Histone acetyltransferase KAT7	0.994	landscape →
Q7S9B6	—	0.994	Q7S9B6 →
Q8WML3	—	0.993	Q8WML3 →
Q5TKR9	—	0.993	Q5TKR9 →
Q810T5	—	0.993	Q810T5 →
Q9LXD7	—	0.992	Q9LXD7 →
Q6CKE9	—	0.992	Q6CKE9 →
KDM5B	Lysine-specific demethylase 5B	0.991	landscape →
KAT6B	Histone acetyltransferase KAT6B	0.991	landscape →
Q8BMD7	—	0.991	Q8BMD7 →
Q6GM71	—	0.991	Q6GM71 →
DHX29	ATP-dependent RNA helicase DHX29	0.991	landscape →
Q2UMQ5	—	0.991	Q2UMQ5 →
BRPF3	Bromodomain and PHD finger-containing protein 3	0.991	landscape →
P91351	—	0.990	P91351 →
Q8BZ21	—	0.990	Q8BZ21 →
KDM5D	Lysine-specific demethylase 5D	0.990	landscape →
Q5A7Q2	—	0.990	Q5A7Q2 →
C8VBH4	—	0.990	C8VBH4 →